文献速递儿童心血管与肾脏

体外膜氧合支持下儿童心脏移植病例分析

[Analysis of pediatric heart transplantation supported by extracorporeal membrane oxygenation].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2024-01-01

回顾性分析12例在ECMO支持下接受心脏移植的终末期心力衰竭患儿,总结其临床特点。4例接受左心减压的患儿脉压显著改善,但LVEF无显著变化。全队列中10例成功脱离ECMO,8例存活出院。

要点

  • ECMO支持的终末期心衰患儿中,扩张型心肌病占多数。
  • 左心减压可显著提升脉压,但对LVEF无显著影响。
  • 术后再次ECMO辅助的患儿中部分可成功脱离并存活出院。

核心结论

  • ECMO支持的终末期心衰患儿,左心减压能显著改善脉压,最终需接受心脏移植。

研究设计与样本

  • 回顾性分析2019年1月至2023年12月两家中心共12例ECMO支持下接受心脏移植的患儿临床资料。

主要发现

  • 12例患儿年龄1.1~15.8岁,体重8~63 kg,10例原发病为扩张型心肌病。
  • ECMO支持前乳酸0.6~>15.0 mmol/L,LVEF 6.5%~43%,VIS 3~108分。
  • 4例接受左心减压,减压后脉压较减压前显著提升[(17.8±2.1)比(9.8±1.5)mmHg,t=11.31,P=0.001]。
  • 左心减压前后LVEF差异无统计学意义[(26.8±4.4)%比(24.9±4.9)%,t=1.75,P=0.178]。
  • 术后7例再次接受ECMO辅助,其中3例成功脱离并存活出院;全队列10例成功脱离ECMO,8例存活出院。

临床怎么用

  • 对ECMO支持的终末期心衰患儿,可考虑左心减压以改善脉压。
  • 此类患儿最终需接受心脏移植,术后可能需要再次ECMO辅助。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To summarize the clinical characteristics of patients with end-stage heart failure who receive heart transplant under extracorporeal membrane oxygenation (ECMO) support. Methods: The clinical data of 12 pediatric patients who received heart transplant with ECMO support in the Seventh Medical Center of Chinese People's Liberation Army General Hospital and Guangdong Provincial People's Hospital, from January 2019 to December 2023 was collected. The data included sex, age, weight, diagnosis, pre-ECMO lactate level, left ventricular ejection fraction (LVEF), vasoactive-inotropic score (VIS), and preoperative ECMO running time. Surgical data included cold ischemia time of the donor heart, cardiopulmonary bypass time, intraoperative use of immunosuppressant, postoperative use of ECMO, duration of postoperative ECMO, rate of successful weaning from ECMO, and survival discharge rate. The paired t-test was performed to compare cardiac function indices before and after left ventricular decompression. Results: The 12 patients ranged in age from 1.1 to 15.8 years, and weighted from 8 to 63 kg. Ten children were diagnosed with dilated cardiomyopathy, one with myocardial underdensification, and one with a novel heterozygous mutation of the SCN5A gene causing overlap syndrome complicated by fatal arrhythmia. Before ECMO, the lactate ranged from 0.6 to>15.0 mmol/L, the LVEF from 6.5% to 43%, and VIS from 3 to 108. Four patients underwent left ventricular decompression supported by preoperative ECMO, and their pulse pressure was significantly increased after decompression ((17.8±2.1) vs. (9.8±1.5) mmHg, 1 mmHg=0.133 kPa, t=11.31, P=0.001), while there was no apparent change in LVEF ((26.8±4.4)% vs. (24.9±4.9)%, t=1.75, P=0.178). A total of 7 children received a second run of ECMO after surgery and 3 of them successfully weaned off ECMO and survived to discharge. In the entire cohort, 10 were successfully weaned from ECMO and 8 survived to discharge. Conclusions: For children with end-stage heart failure supported by ECMO, left ventricular decompression can significantly improve pulse pressure. These patients will eventually require heart transplantation. 目的: 总结体外膜氧合(ECMO)支持下终末期心力衰竭患儿行心脏移植的病例特点。 方法: 回顾性分析2019年1月至2023年12月解放军总医院第七医学中心和广东省人民医院于ECMO支持下行心脏移植的12例患儿的临床资料,包括患儿性别、年龄、体重、所患疾病以及ECMO支持前乳酸水平、左心室射血分数(LVEF)及血管活性药物指数(VIS)、术前ECMO支持时间及左心减压等信息。收集全部患儿心脏移植手术相关信息(包括供心冷缺血时间、体外循环时间、术中免疫抑制剂)、术后重复使用ECMO情况、术后ECMO时间以及患儿是否成功脱离ECMO、是否存活出院等,左心减压前后采用配对t检验。 结果: 12例患儿年龄1.1~15.8岁,体重8~63 kg,10例患儿原发病为扩张型心肌病,1例心肌致密化不全,1例SCN5A基因新发杂合突变致重叠综合征并发致死性心律失常,ECMO支持前患儿乳酸0.6~>15.0 mmol/L,LVEF 7%~43%,VIS 3~108分。4例患儿接受经胸小切口左心减压,减压后脉压较减压前有明显提升[(17.8±2.1)比(9.8±1.5)mmHg,1 mmHg=0.133 kPa,t=11.31,P=0.001],LVEF差异无统计学意义[(26.8±4.4)%比(24.9±4.9)%,t=1.75,P=0.178]。术后共有7例患儿再次接受ECMO辅助,其中3例患儿成功脱离ECMO并存活出院。12例接受移植患儿中10例成功脱离ECMO,8例患儿存活转出重症监护病房。 结论: 行ECMO支持的终末期心力衰竭患儿,左心加压能显著改善脉压,最终需接受心脏移植手术。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhao Z, Zhou CB, Liu AH, et al. [Analysis of pediatric heart transplantation supported by extracorporeal membrane oxygenation]. Zhonghua Er Ke Za Zhi. 2024. PMID: 39039880. doi:10.3760/cma.j.cn112140-20240615-00401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。